Benign autoimmunity to combat malignancy

Clinical and Experimental Immunology

Volumn 125, Issue 1, 2001, Pages 1-2

  Stauss, H J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cancer antigens; Cancer autoimmunity; CENP F; p62

Indexed keywords

COMPLEMENTARY DNA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN CENP F; PROTEIN P62; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; AUTOIMMUNITY; B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH;

AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; CARCINOMA, HEPATOCELLULAR; CHROMOSOMAL PROTEINS, NON-HISTONE; HUMANS; LIVER NEOPLASMS; MICROFILAMENT PROTEINS; RNA-BINDING PROTEINS; T-LYMPHOCYTES;

EID: 0034900271     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01611.x     Document Type: Editorial

References (21)

1. The concept of immunological surveillance
2. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
3. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
4. Human tumor antigens recognized by T lymphocytes
5. Human neoplasms elicit multiple specific immune responses in the autologous host
6. Serological identification of human tumor antigens
7. New paths in human cancer serology
8. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis
9. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma
10. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma
11. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F
12. CD4 (+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma
13. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells
14. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
15. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
16. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production
17. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus
18. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy
19. Targeting p53 as a general tumor antigen
20. Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1
21. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes